


**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu

UCI 17-07 Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment (Ahlering)


UCI 17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

UCI 18-36** Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients with Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Polaris® Test) (Uchio)




****Opening soon**

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu



**Opening soon

For more details contact
 1-877-UC-STUDY or ucstudy@uci.edu



UCI 15-77 A Phase II Clinical Trial to study the efficacy and safety of Pembrolizumab (MK-3475) in subjects with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy (Uchio)

UCI 17-18 A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy (Mar)

- Cohort 2: Platinum-naïve and cisplatin ineligible

UCI 18-35 A Phase II, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) (Uchio)

UCI 18-52** A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients with or without Papillary NMIBC (RITE-USA) (Uchio)


UCI 18-53** A Phase III, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with Intermediate or High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) (Uchio)

UCI 18-54** An Open-Label, Randomized Phase III Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (Mar)

UCI 18-102** A Phase III, Randomized, Study of Neoadjuvant Chemotherapy Alone versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder Cancer (Uchio)

**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu



**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu